Up­dat­ed: Akero says pos­i­tive PhI­Ib da­ta buck the gloomy NASH tide, but ques­tions re­main on safe­ty front

In NASH, pos­i­tive read­outs don’t come too of­ten. Yet ac­cord­ing to Akero, to­day is that day.

Akero Ther­a­peu­tics re­port­ed re­sults from its 24-week HAR­MO­NY Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER